GPX Medical
Every day, one in ten babies are born preterm, many of them with underdeveloped lungs that can advance to life-threatening conditions during their stay in the hospital and risk disabilities later on in life. They deserve a better start in life and health care professionals need support of modern technology to make life-changing decisions that can improve the health of these fragile patients.
GPX Medical’s groundbreaking innovation NEOLA® will upgrade today’s neonatal intensive care to include continuous lung monitoring and real-time alerts of life-threatening complications.
We are on a journey to revolutionize neonatal intensive care
Lung monitoring with NEOLA
GPX Medicals’ proven technology uses laser spectroscopy to continuously measure lung volume changes and oxygen gas concentration in the lungs of preterm born infants. This is a safe and non-invasive method to monitor the lungs of these vulnerable patients in real time, providing the possibility of instant detection and treatment of complications and thus improving the care and decreasing the risk of disabilities later in life.
Sinusitis diagnostics
Sinusitis is a common and painful disease most often caused by viral infections that do not respond to antibiotics. However, over prescription of antibiotics presents a significant global health issue. An accurate and objective measurement of the sinus’ gaseous content can play an important diagnostic role and thereby decrease over prescription of antibiotics.
For Investors
We are on a journey to revolutionize neonatal intensive care
Learn more about investing in GPX Medical
Latest News from GPX Medical
GPX Medical AB (publ) publicerar bolagsbeskrivning inför notering på Nasdaq First North Growth Market
Nasdaq Stockholm AB har per den 29 september 2020 godkänt GPX Medical AB...
